Mercer Global Advisors
LXRX icon

Mercer Global Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Mercer Global Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.76K Buy
+1,567
New +$3.05K ﹤0.01% 5433

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Mercer Global Advisors's LXRX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Lexicon Pharmaceuticals (LXRX) in Q2 2026: 1,567 shares worth $3.76K. The stake represents ﹤0.01% of the portfolio and ranks #5433 among its holdings.

102 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Mercer Global Advisors held 1,567 shares of Lexicon Pharmaceuticals worth $3.76K as of Q2 2026.
  • Lexicon Pharmaceuticals was a new Mercer Global Advisors position in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5433 holding.
  • 102 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.